Autopsy report · NCT03439033

Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer

“Study Drug was FDA approved Summer 2021”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 3 years 1 month before it stopped.
• 273 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

PET/MRI with Gallium-68 labeled PSMA-HBED-CC; Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC; PET/CT with Gallium-68 labeled PSMA-HBED-CC

Participants

273

Sites

1

Countries

United States

Trials that died the same way

• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (74% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (73% match in meaning)
• Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
  “Recent FDA approval of a new drug for the same patient population” (73% match in meaning)
• A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease
  “study intervention was approved by the FDA” (73% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.